Bio-stenting landscape

Although it is not first to market in the coated stent arena, Johnson & Johnson set a high mark for others to match with the announcement that its Cypher sirolimus-eluting coronary stent reduced the incidence of restenosis to zero in its RAVEL trial. But competitors say they are not discouraged, because the data validate the concept of drug-eluting stents and because the results are relatively short-term, leaving the long-term benefits still undetermined.

Stenting of vessels is done to prevent reocclusion after angioplasty. But the process is imperfect,

Read the full 867 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers